Page 99 - Read Online

Page 14 of 16 D’Amico et al. J Cancer Metastasis Treat 2021;7:3 I http://dx.doi.org/10.20517/2394-4722.2020.93

figures/cancer-facts-figures-2020.html. [Last accessed on 21 Sep 2020]
2. Colleoni M, Sun Z, Price KN, et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the
international breast cancer study group trials I to V. J Clin Oncol 2016;34:927-35.
3. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2016 National Cancer Institute. Bethesda MD. Posted to
the SEER web site, April 2019. Available from: https://seer.cancer.gov/csr/1975_2016. [Last accessed on 21 Sep 2020]
4. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J
Med 2004;351:781-91.
5. Bredemeier M, Kasimir-Bauer S, Kolberg HC, et al. Comparison of the PI3KCA pathway in circulating tumor cells and corresponding
tumor tissue of patients with metastatic breast cancer. Mol Med Rep 2017;15:2957-68.
6. Huang ZH, Li LH, Hua D. Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients.
Cancer Lett 2006;243:64-70.
7. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl
Med 2014;6:224ra24.
8. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med
2013;368:1199-209.
9. Madic J, Kiialainen A, Bidard FC, et al. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer
patients. Int J Cancer 2015;136:2158-65.
10. Rodriguez BJ, Córdoba GD, Aranda AG, et al. Detection of TP53 and PIK3CA Mutations in Circulating Tumor DNA Using Next-
Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis. J Clin Med 2019;8:1183.
11. Alimirzaie S, Bagherzadeh M, Akbari MR. Liquid biopsy in breast cancer: A comprehensive review. Clin Genet 2019;95:643-60.
12. Chen KZ, Lou F, Yang F, et al. Circulating tumor DNA detection in early-stage non-small cell lung cancer patients by targeted sequencing.
Sci Rep 2016;6:31985.
13. Zhang XF, Ju SQ, Wang XD, Cong H. Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for
detection and monitoring of breast cancer. Clin Exp Med 2019;19:271-9.
14. Beaver JA, Jelovac D, Balukrishna S, et al. Detection of cancer DNA in plasma of early stage breast cancer patients. Clin Cancer Res
2014;20:2643-50.
15. Phallen J, Sausen M, Adleff V, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med
2017;9:eaan2415.
16. Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science
2018;359:926-30.
17. Salido-Guadarrama I, Romero-Cordoba S, Peralta-Zaragoza O, Hidalgo-Miranda A, Rodríguez-Dorantes M. MicroRNAs transported by
exosomes in body fluids as mediators of intercellular communication in cancer. Onco Targets Ther 2014;7:1327-38.
18. Gold B, Cankovic M, Furtado LV, Meier F, Gocke CD. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have
clinical utility? A report of the association for molecular pathology. J Mol Diagn 2015;17:209-24.
19. Shen SY, Singhania R, Fehringer G, et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature
2018;563:579-83.
20. Liu M, Oxnard G, Klein E, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free
DNA. Annals of Oncology 2020;31:745-59.
21. Cristiano S, Leal A, Phallen J, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature 2019;570:385-9.
22. Gerratana L, Davis AA, Shah AN, Lin C, Corvaja C, Cristofanilli M. Emerging Role of Genomics and Cell-Free DNA in Breast Cancer.
Curr Treat Options Oncol 2019;20:68.
23. Koboldt DC, Fulton RS, McLellan MD, et al. Comprehensive molecular portraits of human breast tumors. Nature 2013;490:61-70.
24. Silva JM, Silva J, Sanchez A, et al. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free
survival. Clin Cancer Res 2002;8:3761-6.
25. Rothé F, Silva MJ, Venet D, et al. Circulating tumor DNA in HER2-amplified breast cancer: a translational research substudy of the
NeoALTTO phase III trial. Clin Cancer Res 2019;25:3581-8.
26. Garcia-Murillas I, Schiavon G, Weigelt B, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci
Transl Med 2015;7:302ra133.
27. Garcia-Murillas I, Chopra N, Comino-Méndez I, et al. Assessment of molecular relapse detection in early-stage breast cancer. JAMA
Oncol 2019;5:1473-8.
28. Chen YH, Hancock BA, Solzak JP, et al. Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative
breast cancer patients with residual disease after neoadjuvant chemotherapy. NPJ Breast Cancer 2017;3:24.
29. Radovich M, Jiang G, Hancock BA, et al. Association of circulating tumor DNA and circulating tumor cells after neoadjuvant
chemotherapy with disease recurrence in patients with triple-negative breast cancer: preplanned secondary analysis of the BRE12-158
randomized clinical trial. JAMA Oncol 2020;6:1410-5.
30. Swanton C, Jamal-Hanjani M, Abbosh C, et al. Phylogenetic ctDNA analysis depicts early stage lung cancer evolution. Nature
2017;545:446-51.
31. Coombes RC, Page K, Salari R, et al. Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clin
Cancer Res 2019;25:4255-63.
32. McDonald BR, Contente-Cuomo T, Sammut SJ, et al. Detection of residual disease after neoadjuvant therapy in breast cancer using